Interventional Glaucoma was Sight Sciences’s largest segment in fiscal 2025, bringing in $75.72M of $77.36M (98%).
| Segment | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Interventional Glaucoma | — | — | $75.90M | $75.72M | ||
| Surgical Glaucoma | $65.59M | $74.31M | — | — | ||
| Interventional Dry Eye | — | — | $3.96M | $1.64M | ||
| Dry Eye | $5.74M | $6.75M | — | — | ||
| Total | $71.33M | $81.06M | $79.87M | $77.36M |
Sight Sciences brought in $77.36M from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 3.1% from $79.87M in fiscal 2024. Interventional Glaucoma was the largest at $75.72M (97.9%), ahead of Interventional Dry Eye at $1.64M (2.1%).
Compared with fiscal 2024, Interventional Glaucoma fell 0.2% to $75.72M and Interventional Dry Eye fell 58.7% to $1.64M.
Sight Sciences began breaking out Interventional Glaucoma in fiscal 2024 and Interventional Dry Eye in fiscal 2024. Sight Sciences stopped reporting Surgical Glaucoma ($74.31M in fiscal 2023) and Dry Eye ($6.75M in fiscal 2023) as separate segments.
Sight Sciences (SGHT) reports its revenue by segment. In fiscal 2025, Interventional Glaucoma was its largest segment, bringing in $75.72M (97.9% of the total), followed by Interventional Dry Eye at $1.64M (2.1%).
Interventional Glaucoma was Sight Sciences' largest segment in fiscal 2025, bringing in $75.72M, or 97.9% of the $77.36M total across its two segments.
Every figure comes from Sight Sciences' annual financial filings, as reported. Each line keeps the name Sight Sciences gives it, and years follow its fiscal calendar.
Sight Sciences' revenue by segment goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.